Analysts Expect Xencor Inc (XNCR) Will Post Quarterly Sales of $15.65 Million
Brokerages expect Xencor Inc (NASDAQ:XNCR) to report $15.65 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Xencor’s earnings. The lowest sales estimate is $10.30 million and the highest is $21.00 million. Xencor posted sales of $6.44 million in the same quarter last year, which indicates a positive year-over-year growth rate of 143%. The firm is scheduled to report its next quarterly earnings results on Tuesday, February 27th.
On average, analysts expect that Xencor will report full year sales of $15.65 million for the current fiscal year, with estimates ranging from $25.30 million to $45.77 million. For the next financial year, analysts anticipate that the business will report sales of $25.33 million per share, with estimates ranging from $19.80 million to $36.20 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that that provide coverage for Xencor.
XNCR has been the topic of several recent analyst reports. Canaccord Genuity set a $36.00 price target on Xencor and gave the company a “buy” rating in a research note on Monday, October 23rd. ValuEngine lowered Xencor from a “hold” rating to a “sell” rating in a research note on Monday, October 23rd. Zacks Investment Research lowered Xencor from a “hold” rating to a “sell” rating in a research note on Saturday, November 11th. Piper Jaffray Companies reissued a “buy” rating and issued a $35.00 price target on shares of Xencor in a research note on Sunday, November 12th. Finally, Cantor Fitzgerald initiated coverage on Xencor in a research note on Wednesday, November 29th. They issued an “overweight” rating and a $33.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the stock. Xencor has an average rating of “Hold” and a consensus target price of $30.80.
In other news, major shareholder John S. Stafford III bought 50,000 shares of the stock in a transaction dated Thursday, November 2nd. The shares were bought at an average cost of $19.58 per share, with a total value of $979,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder John S. Stafford III bought 150,000 shares of the stock in a transaction dated Friday, October 27th. The shares were purchased at an average cost of $19.81 per share, for a total transaction of $2,971,500.00. The disclosure for this purchase can be found here. Insiders have bought 278,535 shares of company stock worth $5,526,936 over the last ninety days. 4.03% of the stock is owned by insiders.
Large investors have recently modified their holdings of the company. Emory University acquired a new position in shares of Xencor during the second quarter worth approximately $1,491,000. Virginia Retirement Systems ET AL raised its position in shares of Xencor by 10.0% during the third quarter. Virginia Retirement Systems ET AL now owns 76,200 shares of the biopharmaceutical company’s stock worth $1,747,000 after purchasing an additional 6,900 shares during the period. State Street Corp raised its position in shares of Xencor by 11.1% during the second quarter. State Street Corp now owns 1,103,455 shares of the biopharmaceutical company’s stock worth $23,295,000 after purchasing an additional 110,474 shares during the period. State of Wisconsin Investment Board acquired a new position in shares of Xencor during the second quarter worth approximately $612,000. Finally, Vanguard Group Inc. raised its position in shares of Xencor by 5.6% during the second quarter. Vanguard Group Inc. now owns 1,701,209 shares of the biopharmaceutical company’s stock worth $35,913,000 after purchasing an additional 90,094 shares during the period. 77.50% of the stock is currently owned by institutional investors.
Xencor (XNCR) opened at $22.83 on Friday. Xencor has a 12 month low of $18.55 and a 12 month high of $28.64. The stock has a market capitalization of $1,090.00, a P/E ratio of -22.60 and a beta of 2.09.
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with Analyst Ratings Network's FREE daily email newsletter.